Oral nanomedicines for the treatment of parasitic diseases

Katerina Lalatsa; Dolores Remedios Serrano Lopez; Lindsay  Smith; Maria Auxiliadora Dea-Ayuela

Oral nanomedicines for the treatment of parasitic diseases

Katerina Lalatsa, Dolores Remedios Serrano Lopez, Lindsay Smith, Maria Auxiliadora Dea-Ayuela

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to conference › Poster › peer-review

Abstract

Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

Original language	English
Number of pages	1
Publication status	Published - 15 Jul 2014
Event	CRS Annual Meeting and Exposition - Chicago, United States Duration: 12 Jul 2014 → 16 Jul 2014

Conference

Conference	CRS Annual Meeting and Exposition
Country/Territory	United States
City	Chicago
Period	12/07/14 → 16/07/14

Keywords

parasitic diseases
oral nanomedicines
drug delivery systems
visceral Leishmaniasis

Cite this

@conference{915bc5ef3fef4981bdde311c1b0bf2d4,

title = "Oral nanomedicines for the treatment of parasitic diseases",

abstract = "Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity. ",

keywords = "parasitic diseases, oral nanomedicines, drug delivery systems, visceral Leishmaniasis",

author = "Katerina Lalatsa and {Serrano Lopez}, {Dolores Remedios} and Lindsay Smith and Dea-Ayuela, {Maria Auxiliadora}",

year = "2014",

month = jul,

day = "15",

language = "English",

note = "CRS Annual Meeting and Exposition<br/> ; Conference date: 12-07-2014 Through 16-07-2014",

}

TY - CONF

T1 - Oral nanomedicines for the treatment of parasitic diseases

AU - Lalatsa, Katerina

AU - Serrano Lopez, Dolores Remedios

AU - Smith, Lindsay

AU - Dea-Ayuela, Maria Auxiliadora

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

AB - Self-nanoemulsifying drug delivery systems (SNEDDs) prepared from GRAS excipients (Labrafil M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w) enhance the oral bioavailability of a poorly soluble antiparasitic drug, Buparvaquone (BPQ), while maintaining in vitro efficacy against L. infantum promastigotes. BPQ-SNEDDs possess high loading and excellent stability to tropical temperatures while allowing for the complete dissolution of BPQ in simulated gastrointestinal media. We hypothesise that the enhanced solubilisation capacity of BPQ in the GI tract is responsible for the enhanced oral bioavailability. Adsorption of prepared BPQ-SNEDDs on solid carriers (glycol chitosan) and lyophilisation resulted in a solid nanomedicine that can be reconstituted to yield stable BPQ-SNEDDs of nanomolar in vitro activity.

KW - parasitic diseases

KW - oral nanomedicines

KW - drug delivery systems

KW - visceral Leishmaniasis

M3 - Poster

T2 - CRS Annual Meeting and Exposition<br/>

Y2 - 12 July 2014 through 16 July 2014

ER -

Oral nanomedicines for the treatment of parasitic diseases

Abstract

Conference

Keywords

Fingerprint

Cite this